• Efavirenz Significantly Reduces Levels of Some Oral Contraceptives (Posted Jan. 30, 2009)
  From HIV i-Base
• Switch to Viramune Safe for Some Who Can't Tolerate Sustiva (Posted Nov. 26, 2008)
  From Project Inform
• Study Shows People Can Safely Switch to Atripla (Posted Nov. 26, 2008)
  From Project Inform
• Evolving Options for First-Line Therapy: Highlights From ICAAC/IDSA 2008 (Posted Nov. 3, 2008)
  David Wohl, M.D., explores the clinical importance of new data from a passel of head-to-head clinical trials in treatment-naive patients, including investigations of abacavir/lamivudine, atazanavir, darunavir, lopinavir/ritonavir, maraviroc, raltegravir and tenofovir/emtricitabine.
  

  Read or listen (31 min.):

  From TheBodyPRO.com
• Reappraising Key Issues in HIV Clinical Management: Highlights From ICAAC/IDSA 2008 (Posted Nov. 3, 2008)
  Benjamin Young, M.D., Ph.D., leads an insightful discussion on new data regarding etravirine and raltegravir; a revisitation of the "when to start" question; alarming disparities in HIV care among U.S. women; and the clinical management of aging HIV-infected patients.
  

  Read or listen (58 min.):

  From TheBodyPRO.com
• Merck's Antiretroviral Isentress More Efficient in Suppressing HIV Among Untreated Patients (Posted Oct. 28, 2008)
  From Henry J. Kaiser Family Foundation
• Antiretroviral Treatment Should Start Earlier, Study Says (Posted Oct. 27, 2008)
  From Henry J. Kaiser Family Foundation
• ICAAC/IDSA 2008 Highlights: Eric Daar, M.D., Summarizes New Studies on HIV Medications (Posted Oct. 27, 2008)
  From atazanavir to fosamprenavir and from darunavir to raltegravir, several clinical trials were presented at ICAAC/IDSA 2008 that may shift the prescribing landscape for HIV clinicians. In this review geared toward the patient population, Dr. Daar provides a rundown of these noteworthy studies and explains their significance.
  

  Read or listen (7 min.):

  From TheBodyPRO.com
• Studies: Newer HIV Drugs More Tolerable for Many (Posted Oct. 27, 2008)
  From U.S. Centers for Disease Control and Prevention
• 96-Week ARTEMIS Data Indicate Darunavir Is Superior to Lopinavir in Naive Patients (Posted Oct. 26, 2008)
  Following 48-week data that proved darunavir's non-inferiority to lopinavir, these new, even more encouraging 96-week data appear likely to solidify the drug's role in first-line therapy. (An interview with Tony Mills, M.D.)
  

  Read or listen (4 min.):

  From TheBodyPRO.com
• Crafting First-Line Regimens: So Easy a General Practitioner Could Do It? (Posted Oct. 26, 2008)
  We may have more antiretrovirals to choose from than ever before, but selecting an initial HAART regimen today is often a choice between just two regimens, a new study indicates. The findings suggest it may be realistic for primary care physicians and general practitioners to shoulder more of the HIV care burden. (An interview with James McKinnell, M.D.)
  

  Read or listen (12 min.):

  From TheBodyPRO.com
• HEAT: Virologic Failure Rates Similar (and Low), Emerging Resistance Uncommon on Abacavir/Lamivudine vs. Tenofovir/Emtricitabine (Posted Oct. 26, 2008)
  The similarities between these two first-line nucleoside backbones is reiterated in a new examination of virologic failure data from the 96-week results of the HEAT study. (An interview with Benjamin Young, M.D., Ph.D.)
  

  Read or listen (10 min.):

  From TheBodyPRO.com
• Large Study Supports Earlier Treatment (Posted Oct. 26, 2008)
  From Project Inform
• RDEA Study Supports Further Development of New NNRTI (Posted Oct. 26, 2008)
  From Project Inform
• Results From Elvucitabine Study Unimpressive (Posted Oct. 26, 2008)
  From Project Inform
• Starting HAART: Should 500 Become the New 350? (Posted Oct. 26, 2008)
  Mari Kitahata, M.D., and Daniel Kuritzkes, M.D., discuss a 5,926-patient trial that found a 74% higher mortality risk among those who deferred HAART until their CD4 dropped below 350 rather than initiating when their CD4 was between 351 and 500. Dr. Kuritzkes also touches on new developments in HIV drug resistance.
  

  Read or listen (35 min.):

  From TheBodyPRO.com
• Study Data Explain Isentress' Excellent Resistance Profile (Posted Oct. 26)
  From Project Inform
• Study May Point Way Forward for Bevirimat (Posted Oct. 26, 2008)
  From Project Inform
• Study Shows Better Results From Vicriviroc When New Trofile Test Is Used (Posted Oct. 26)
  From Project Inform
• Study Supports Use of Isentress for First-Line Treatment (Posted Oct. 26, 2008)
  From Project Inform
• Switching From Combivir to Truvada Keeps HIV Undetectable, Improves Blood Fats, But Fails to Improve Limb Fat (Posted Oct. 26, 2008)
  From Project Inform
• Trend Toward Fewer AIDS-Defining Conditions Among Patients Receiving Raltegravir vs. Placebo (Posted Oct. 26, 2008)
  A new examination of 48-week BENCHMRK data found a nearly twofold reduction in AIDS-defining events among patients on raltegravir, but the findings failed to reach statistical significance. Intriguingly, greater resistance did not appear to be a predictor of AIDS-defining events. (An interview with Joseph Eron Jr., M.D.)
  

  Read or listen (7 min.):

  From TheBodyPRO.com

The Body PRO's coverage of the 48th Annual ICAAC®/IDSA 46th Annual Meeting (ICAAC®/IDSA 2008) will include a wide array of individual presentations and symposia, as well as summaries of some of the hottest topics in HIV research.*

For more information on ICAAC®/IDSA 2008, please visit the conference's Web site. You may also view the conference program planner online.

*ICAAC® is a registered trademark of the American Society for Microbiology Corporation. Neither Body Health Resources Corporation nor its corporate parent, The HealthCentral Network, Inc. is affiliated with the ICAAC Conference or the American Society for Microbiology Corporation.